[Granular lymphocyte-proliferative disorder following initiation of protease inhibitor therapy in a patient with acquired immunodeficiency syndrome].
The authors experienced granular lymphocyte-proliferative disorder (GLPD) with increased lymphocyte and CD4 cell counts after HIV treatment with a protease inhibitor indinavir in a 51-year-old male AIDS patient. GLPD proved to be the chronic type, but we could not differentiate whether it was the T-cell type or the NK-cell type. EB virus was found to be activated and its chronic activity was suggested. We should note in this case that EB virus was involved in the GLPD onset and that GLPD followed the treatment with a protease inhibitor.
Tanaka
K
K
First Department of Internal Medicine, Kurume University School of Medicine.
Honda
J
J
Shiraishi
K
K
Jojima
H
H
Tanaka
M
M
Okubo
Y
Y
Fukahori
S
S
Fujimatsu
Y
Y
Oizumi
K
K
D017088:AIDS-Related Opportunistic Infections; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006566:Herpesviridae Infections; D004854:Herpesvirus 4, Human; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use*; D008232:Lymphoproliferative Disorders / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D014412:Tumor Virus Infections
D017320:HIV Protease Inhibitors; D019469:Indinavir